DONALD PARSONS to United States
This is a "connection" page, showing publications DONALD PARSONS has written about United States.
Connection Strength
0.233
-
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
Score: 0.079
-
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234.
Score: 0.068
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
Score: 0.019
-
Physician-Scientist Training and Programming in Pediatric Residency Programs: A National Survey. J Pediatr. 2022 02; 241:5-9.e3.
Score: 0.016
-
Fixing the leaky pipeline: identifying solutions for improving pediatrician-scientist training during pediatric residency. Pediatr Res. 2020 08; 88(2):163-167.
Score: 0.015
-
The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations. Am J Hum Genet. 2018 09 06; 103(3):319-327.
Score: 0.013
-
Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
Score: 0.012
-
Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet. 2016 06 02; 98(6):1051-1066.
Score: 0.011